European urology focus最新文献

{"title":"\"I think that there is a lack of information and awareness\": A PRAISE-U Clinical Trial Update.","authors":"Grace McKinney, Mette Bach Larsen, Angel Gomez Amorin, Sofie Meyer Andersen, Marina Tarrazo Antelo, Anna Arnau Bartes, Gemma Cuberas Borros, Arunah Chandran, Sarah Collen, David Galvin, Katarzyna Hodyra-Stefaniak, Gillian Horgan, Monika Litwin, Ugnė Mickevičiūtė, Aušvydas Patašius, Montserrat Corujo Quinteiro, Monique J Roobol, Krzysztof Tupikowski, Roderick C N van den Bergh, Hendrik Van Poppel, Lionne D F Venderbos, Josep Maria Vilaseca, Pia Kirkegaard","doi":"10.1016/j.euf.2026.07.015","DOIUrl":"https://doi.org/10.1016/j.euf.2026.07.015","url":null,"abstract":"<p><p>PRostate cancer Awareness and Initiative for Screening Europe (PRAISE-U) is a project testing organized, risk-stratified prostate cancer screening. Micro-, meso-, and macrolevel stakeholders involved in PRAISE-U are participating in collaborative user boards. These stakeholders have identified themes including men's health beliefs, accessibility of screening, and considerations for success.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En-bloc Resection of Bladder Tumor Versus Conventional Transurethral Resection of Bladder Tumor: Long-term Oncological Outcomes from a Single-center Prospective Trial.","authors":"Francesco Di Bello, Pietro Diana, Andrea Gallioli, Angelo Territo, Óscar Rodriguez-Faba, Josep M Gaya, Jordi Huguet, André R Belarmino, Marta Lopez, Giulio Avesani, Giorgio Graps, Ferran Algaba, Joan Palou, Alberto Breda","doi":"10.1016/j.euf.2026.07.008","DOIUrl":"https://doi.org/10.1016/j.euf.2026.07.008","url":null,"abstract":"<p><p>Prior randomized trials have shown that en bloc transurethral resection of bladder tumor (ERBT) is noninferior to conventional transurethral resection of bladder tumor (cTURBT) for pathological staging. To address gaps in long-term oncologic outcomes, we conducted a post hoc analysis of a single-center randomized trial including 219 of the 248 patients treated between 2018 and 2021, evaluating overall survival (OS), cancer-specific survival (CSS), and cumulative incidence of urothelial recurrence with a median follow-up of 60 mo (interquartile range = 53-79). ERBT was performed in 124 patients (57%) and cTURBT in 95 (43%). Overall, 77 patients experienced recurrence. With updated follow-up, 60-mo cumulative urothelial recurrence rates ranged from 8% (95% confidence interval [CI] = 2-14) for cTURBT to 10% (95% CI = 5-18) for ERBT. Even after competing-risk multivariable adjustment for overall mortality, as well as age, sex, tumor stage and grade, comorbidities (hypertension and diabetes mellitus), prior bladder tumor, and adjuvant therapy, recurrence rates did not differ between ERBT and cTURBT. Rates of upgrading (low grade to high grade) and upstaging (Tx/Ta/T1-T2) were also similar between groups. During follow-up, 41 patients died, including 5 bladder cancer-related deaths; 60-month OS was 76% (95% CI = 68-86) for cTURBT and 83% (95% CI = 76-90) for ERBT, with no difference in 60-mo CSS (97% vs 97%).</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical Prostatectomy Without Prior Biopsy? Final Histopathology of Radical Prostatectomies in 103 Consecutive Biopsy-naïve Patients Who Underwent Radical Prostatectomy.","authors":"Marie Semmler, Julian Marcon, Elena K Berg, Gerald B Schulz, Patrick Keller, Darjusch Askari, Sarah Takayama Fouladgar, Benazir Enzinger, Benedikt Ebner, Paulo L Pfitzinger, Stephan Ledderose, Philipp M Kazmierczak, Lennert Eismann, Alexander Buchner, Philipp Weinhold, Christian G Stief, Robert Bischoff","doi":"10.1016/j.euf.2026.06.030","DOIUrl":"https://doi.org/10.1016/j.euf.2026.06.030","url":null,"abstract":"<p><strong>Background and objective: </strong>Prostate biopsy for histological confirmation is the standard before radical prostatectomy (RP). However, some patients refuse biopsy despite highly suspicious imaging findings. This study aimed to evaluate final pathology, assess potential active surveillance (AS) eligibility, and exploratorily evaluate perioperative outcomes and short-term oncological biochemical recurrence (BCR)-free survival after biopsy-naïve RP (bnRP).</p><p><strong>Methods: </strong>We retrospectively analyzed a single-center cohort of patients who underwent bnRP with pT2-pT3 disease between 2019 and 2026. Final pathology was assessed, and potential AS eligibility was approximated using European Association of Urology-based low-risk and favorable intermediate-risk categories. Perioperative outcomes and short-term BCR-free survival were exploratorily compared between patients who underwent bnRP and those who underwent biopsy-confirmed RP (bcRP) using Kaplan-Meier estimation, log-rank testing, and a univariable Cox proportional hazards model.</p><p><strong>Key findings and limitations: </strong>In 103 consecutive bnRP specimens, prostate cancer was confirmed in all patients. Overall, 94% had clinically significant prostate cancer (csPCa). Compared with 3081 consecutive patients who underwent bcRP, patients who underwent bnRP had fewer low-grade tumors and more locally advanced disease. Overall, 5.8% of the biopsy-naïve patients had International Society of Urological Pathology grade group 1 disease, but only one patient fulfilled the stricter AS approximation criteria. However, in total, 18% of the biopsy-naïve patients fulfilled broader AS criteria and might have warranted formal AS assessment. Exploratory analysis revealed no significant difference in short-term BCR-free survival between patients who underwent bnRP and those who underwent bcRP.</p><p><strong>Conclusions and clinical implications: </strong>In our single-center observational analysis of carefully selected patients, bnRP seemed safe and was associated with a high likelihood of csPCa. Nevertheless, the retrospective approximation of AS eligibility highlights that bnRP should be performed cautiously. Exploratory perioperative and short-term oncological analyses need prospective validation.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeated Renal Interventions for Renal Cell Carcinoma in von Hippel-Lindau Disease: Long-Term Outcomes.","authors":"C A Jilg, S C Astheimer, F Kotsis, A Ganner, W Schultze-Seemann, H P Neumann, M T Grabbert, S Spohn, S Kirste, C Gratzke, E Neumann-Haefelin, R Himmelsbach","doi":"10.1016/j.euf.2026.07.002","DOIUrl":"https://doi.org/10.1016/j.euf.2026.07.002","url":null,"abstract":"<p><p>Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome frequently associated with recurrent renal cell carcinoma (RCC), often requiring multiple renal interventions. Data on the timing and outcomes of repeated renal procedures remain limited. This study aimed to characterize patterns, timing, and outcomes of repeated renal interventions in VHL disease. Retrospective single-center analysis of 89 patients with VHL undergoing repeated renal interventions for RCC, including nephron-sparing surgery (NSS), nephrectomy, and minimally invasive interventions. Time to repeated interventions was assessed using kidney- and patient-based Kaplan-Meier analyses. Outcomes included perioperative parameters, metastasis, and overall survival. A total of 232 renal interventions were performed, with a median of two procedures per patient and a median follow-up of 14.6 yr. Among 204 surgical interventions (167 NSS, 37 nephrectomies), operative time, blood loss, and length of hospital stay were comparable. Kidney-based analyses (n = 178) showed median intervals of 10.7 and 8.2 yr between successive ipsilateral procedures, while nephrectomy occurred after a median of 24.6 yr. Patient-based analyses demonstrated median times of 4.9, 6.4, and 2.6 yr to the second, third, and fourth interventions. Metastases occurred in 10 patients, and median overall survival from first intervention was 20.9 yr. Perioperative complications were more frequent after NSS, whereas high-grade complications (Clavien-Dindo grade 4 or higher) were rare. Limitations include the single-center design and selected patient population. Repeated renal interventions are common in VHL disease. Organ-preserving strategies allow long-term renal preservation with acceptable oncologic outcomes and low rates of severe complications. Referral to experienced centers is recommended.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ureteroscopy in Patients Receiving Systemic Anticoagulants: A Systematic Review and Meta-analysis of Safety, Efficacy, and Perioperative Management.","authors":"Donnacha Hogan, Stefanie M Croghan, Bhaskar K Somani, Olivier Traxer, Andreas Skolarikos, Rob Geraghty, Lazaros Tzelves, Niall F Davis","doi":"10.1016/j.euf.2026.05.023","DOIUrl":"https://doi.org/10.1016/j.euf.2026.05.023","url":null,"abstract":"<p><strong>Context: </strong>To evaluate the safety and efficacy of ureteroscopy (URS) in adults receiving systemic anticoagulant (AC) therapy, including vitamin K antagonists and direct oral anticoagulants (DOACs), compared with non-AC controls.</p><p><strong>Objective: </strong>Using a Population, Intervention, Comparator, Outcomes (PICO) framework, we examined whether continuation, interruption, or peri-operative bridging of AC influences bleeding complications, thromboembolic events, and stone-free rates (SFR) in adults undergoing URS for stone disease.</p><p><strong>Evidence acquisition: </strong>A systematic review of PubMed, Embase, and Scopus identified studies reporting URS outcomes in anticoagulated patients. The review adhered to PRISMA standards and was registered with PROspective Register of Systematic Reviews (PROSPERO) (Centre for Reviews and Dissemination (CRD)420251154766). Studies limited to antiplatelet monotherapy were excluded. Random-effects meta-analysis was performed for outcomes where sufficient comparative data were available. SFR was summarised descriptively. Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I).</p><p><strong>Evidence synthesis: </strong>Eleven studies (1,516 AC patients; 20,708 controls) published between 1998 and 2024 met inclusion criteria. Anticoagulation was not associated with a statistically significant increase in overall postoperative complications (RR 1.83, 95% CI 0.95-3.52). Bleeding-related complications were variably reported across studies, with absolute event rates ranging from 0-20% in anticoagulated patients and 0-0.60% in controls. In the largest comparative cohort, bleeding occurred in 1.1% (8/702) of anticoagulated patients versus 0.40% (44/10,859) of controls. Thirty-day readmission rates did not differ significantly (RR 1.59, 95% CI 0.27-9.29). SFRs ranged between 70-97% across studies. Most studies were judged at serious risk of bias, primarily due to non-random allocation of AC strategies.</p><p><strong>Conclusions: </strong>Bleeding complications were variably reported across studies, with several observational cohorts reporting higher absolute bleeding rates in anticoagulated patients than controls, although definitions were heterogeneous and absolute event rates were low. Thromboembolic events were rare. Continuation may be justified in carefully selected high-thrombotic-risk patients.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection.","authors":"Jay Ogunkeye, Eugene Shkolyar, Kathleen E Mach, Sophia Prendiville, Kris Prado, Jay B Shah, Eila C Skinner, Daniel S Fischer, Kevin G Phillips, Vincent T Bicocca, Trevor G Levin, Joseph C Liao","doi":"10.1016/j.euf.2026.06.002","DOIUrl":"https://doi.org/10.1016/j.euf.2026.06.002","url":null,"abstract":"<p><strong>Background and objective: </strong>Patients with high-risk non-muscle invasive bladder cancer (NMIBC) experience high recurrence rates and potential understaging, supporting guideline recommendations for repeat transurethral resection (reTUR). However, identifying patients best suited for reTUR remains challenging. Here, we analyze urine tumor DNA (utDNA) for mutations associated with urothelial cancer in a cohort of patients undergoing reTUR.</p><p><strong>Methods: </strong>Retrospective evaluation of urine samples from 43 patients with pathologically confirmed high-grade NMIBC who were undergoing reTUR. Urine was collected immediately prior to reTUR and evaluated using UroAmp. The primary objective of this study was to compare utDNA disease classification with pathological staging from reTUR. Prognostic (high/low-risk) and minimal residual disease (MRD) (positive/negative) classifications were evaluated.</p><p><strong>Key findings and limitations: </strong>The stage distribution from reTUR was 32% T0 (no residual disease), 29% Ta ±CIS, 28% T1 ±CIS, and 11% T2. Prognostic risk classification had 97% sensitivity (95% confidence interval [CI] 86-100) and 89% negative predictive value (95% CI 59-99). MRD classification had 80% specificity (95% CI 56-94) and 88% positive predictive value (95% CI 72-97). When long-term recurrence outcomes were considered, positive predictive value increased to 92% (95% CI 78-98) for both classification algorithms. Among T0 samples, utDNA high-risk patients had recurrence-free survival of 36%, compared to 100% for utDNA low-risk patients (p = 0.006).</p><p><strong>Conclusions and clinical implications: </strong>utDNA testing identifies residual disease prior to reTUR. utDNA can serve as an adjunct following initial transurethral resection, aiding in the assessment of resection completeness, determining the need and timing of repeat resection, and stratifying risk of future recurrence.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.","authors":"Luca Antonelli, Luca Afferi, Francesco Del Giudice, Eugenio Bologna, Francesco Esperto, Francesco Chierigo, Alessandro Antonelli, Karl Tully, Paolo Umari, Simone Albisinni, Andrea Mari, Renate Pichler, Francesco Claps, Jeremy Yuen-Chun Teoh, Mathieu Roumiguié, Gerald Bastian Schulz, Luca Orecchia, Francesco Soria, Morgan Roupret, Gautier Marcq, Cedric Poyet, Girish S Kulkarni, Michael Rink, Tobias Klatte, Riccardo Campi, Wojciech Krajewski, Laura Mertens, Meftun Culpan, Luke T Lavallée, Marco Moschini, Christian Daniel Fankhauser","doi":"10.1016/j.euf.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.euf.2026.07.009","url":null,"abstract":"<p><strong>Background: </strong>Radical cystectomy with pelvic lymph node dissection (PLND) remains the standard treatment for muscle-invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) improves survival, and recent immunochemotherapy trials have reported complete pathological responses in up to 60% of patients, increasing interest in bladder-sparing strategies. However, the ability to accurately identify patients without residual pelvic lymph node metastases after NAC remains limited.</p><p><strong>Objective: </strong>To evaluate the association between pathological response in the bladder and pelvic lymph node status after NAC in patients with MIBC undergoing radical cystectomy (RC) and PLND.</p><p><strong>Design, setting, and participants: </strong>This retrospective, multi-institutional cohort study included 751 patients with MIBC treated with NAC followed by RC and PLND between 2000 and 2021 across 26 institutions.</p><p><strong>Intervention: </strong>Neoadjuvant chemotherapy followed by RC and PLND.</p><p><strong>Outcome measurements and statistical analysis: </strong>The primary outcome was residual lymph node involvement (ypN+). Multivariable logistic regression was used to identify factors associated with ypN+.</p><p><strong>Results and limitations: </strong>Overall, 175 patients (23%) achieved a complete pathological response in the bladder (ypT0), 102 (14%) were downstaged to non-muscle-invasive disease (ypTa/ypTis/ypT1), and 185 (25%) had residual lymph node involvement. On multivariable analysis, cN+ disease before NAC was associated with higher odds of ypN+ (OR 1.97, 95% CI 1.32-2.94), whereas ypT0 (OR 0.11, 95% CI 0.05-0.21) and ypTa/ypTis/ypT1 (OR 0.24, 95% CI 0.12-0.47) were associated with lower odds of ypN+. Notably, 5% of ypT0 and 10% of downstaged patients harboured residual lymph node metastases. Limitations include potential selection bias and centre-level variability in surgical and pathological assessment, which may affect the generalizability of the findings.</p><p><strong>Conclusions: </strong>Current clinical and radiological variables cannot reliably exclude residual pelvic lymph node disease, even in patients achieving ypT0-1. Novel imaging techniques and liquid biomarkers require validation before bladder-sparing approaches can be safely expanded.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?","authors":"Valentino Dragonetti, Francesco Mattana, Francesco Ceci","doi":"10.1016/j.euf.2026.05.024","DOIUrl":"https://doi.org/10.1016/j.euf.2026.05.024","url":null,"abstract":"<p><strong>Background: </strong>Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) has been established as a key treatment for PSMA-positive metastatic castration-resistant prostate cancer following the approval of [¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu). However, variable responses, resistance, uncertain treatment sequencing, and limited efficacy in selected biological settings remain major clinical challenges. This narrative perspective reviews the rationale for radionuclide selection in PSMA-targeted therapy.</p><p><strong>Evidence acquisition: </strong>A nonsystematic review of PubMed/MEDLINE and EMBASE was performed, updated to April 2026, prioritizing registered trials and multicenter studies.</p><p><strong>Evidence synthesis: </strong>¹⁷⁷Lu remains the clinical benchmark owing to randomized evidence, favorable logistics, posttherapy imaging, and a well-defined safety profile. Its β-emission crossfire effect is useful in bulky or heterogeneous disease but may be less effective against micrometastatic or PSMA-low/aggressive clones. Actinium-225-based targeted α-therapy offers high linear energy transfer radiation and may overcome β-emitter resistance, although side effects, imaging limitations, and supply constraints remain concerns. Terbium-161 (¹⁶¹Tb) may provide a valid alternative with potential advantages in small-volume disease.</p><p><strong>Conclusions: </strong>Early data with ¹⁶¹Tb- and Lead-212-based PSMA therapies are promising but require prospective comparative validation. Future progress will depend on matching radionuclide properties to tumor biology rather than identifying a universally superior isotope.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial.","authors":"Gemma Sheehan-Dare, Sobia Khan, Louise Emmett","doi":"10.1016/j.euf.2026.07.006","DOIUrl":"https://doi.org/10.1016/j.euf.2026.07.006","url":null,"abstract":"<p><p>A key unanswered question in prostate-specific membrane-antigen (PSMA) targeted radioligand therapy is whether we have chosen therapy doses and regimens that are \"safe\" rather than \"effective,\" with phase 3 trials to date guided by conservative external beam derived dose constraints. However, is increasing administered dose or short interval fractionated dose safe, and does it even make a difference to patient outcomes? The goal of the OPTIMAL-PSMA trial is to determine the depth of response and safety of intense-induction then maintenance dosing compared to standard-of-care six doses 6-weekly [¹⁷⁷Lu] Lu-PSMA-597 in men with metastatic castration-resistant prostate cancer (mCRPC). This mini review will evaluate the scientific evidence and rationale for dose intensification with PSMA-targeted radioligand therapy (PSMA-RLT). It will cover existing trials that are evaluating a variety of dose-dense regimens and give a more in-depth overview of the OPTIMAL-PSMA trial.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Schwartzmann and Silvestri's Letter to the Editor re: Ritter Manuel, Stein Johannes, Barber Neil, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. Eur Urol Focus 2026;12:266-274.","authors":"Manuel Ritter, Robert Németh, Matthias Schmid, Johannes Stein","doi":"10.1016/j.euf.2026.06.024","DOIUrl":"https://doi.org/10.1016/j.euf.2026.06.024","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}